BioWorld

Oct. 18, 2004

View Archived Issues

CoTherix Prices IPO Low, Raises $30M For Ventavis

Read More

MacroGenics Raises $30M In Second-Round Financing

Read More

ViRexx Enters Agreement To Buy Familiar Firm: AltaRex

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

La Jolla's Riquent Approvable Letter: Finished Study Needed

La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. (BioWorld Today) Read More

Hardy Attempt' At H&Q-Style Meeting Wins Attendee Praise

Read More